Compare ResMed Inc. (RMD) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Schlumberger NV — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Schlumberger NV trades at $57.14 (market cap $84.74B). The key difference: Schlumberger NV is far larger — about 2.7× ResMed Inc.'s market cap, and Schlumberger NV pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| RMD | SLB | |
|---|---|---|
Market Cap | $31.89B | $84.74B |
Sector | Health | Energy |
52-Week High | $283.28 | $60.10 |
52-Week Low | $182.82 | $31.72 |
Enterprise Value | $31.24B | $93.47B |
Dividend Yield | 1.19% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
SLB trades at $57.10, down 0.71% on the day, but remains near recent highs with a bullish technical trend. The company reported three consecutive quarterly earnings beats, with Q3 2026 expected at $0.62 EPS. Recent news highlights the $3.4 billion acquisition of Kelvion, expanding SLB's data center cooling business. Revenue for 2025 was $35.71 billion with a net income margin of 8.53%, though margins have softened from prior years. Analyst consensus is strongly bullish with an average price target of $63.00.
The outlook for SLB is positive, driven by strategic diversification into data centers and solid operational cash flow near $6.5 billion annually. Key risks include exposure to oil price volatility and integration challenges from the Kelvion deal. With 85% of analysts rating it a buy, the stock offers upside potential but requires monitoring of execution on new growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
